Cargando…

Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo

Human papillomavirus (HPV) infections are transmitted through sexual or other close contact and are etiologically associated with epithelial warts, papillomas, and intraepithelial lesions that may progress to cancer. Indeed, 4.8% of the global cancer burden is linked to HPV infection. Highly effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Jesse M., Zine El Abidine, Amira, Gómez-Martinez, Ricardo A., Bondu, Virginie, Sterk, Rosa T., Surviladze, Zurab, Ozbun, Michelle A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765401/ https://www.ncbi.nlm.nih.gov/pubmed/34723633 http://dx.doi.org/10.1128/AAC.01513-21

Ejemplares similares

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus
por: Levendosky, Keith, et al.
Publicado: (2015)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
por: Bonnard, Damien, et al.
Publicado: (2023)

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
por: Vigil, Adam, et al.
Publicado: (2018)

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015)

The Known and Potential Intersections of Rab-GTPases in Human Papillomavirus Infections
por: Young, Jesse M., et al.
Publicado: (2019)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus
por: Su, Hang, et al.
Publicado: (2021)

6′-β-Fluoro-Homoaristeromycin and 6′-Fluoro-Homoneplanocin A Are Potent Inhibitors of Chikungunya Virus Replication through Their Direct Effect on Viral Nonstructural Protein 1
por: Kovacikova, Kristina, et al.
Publicado: (2020)

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
por: Good, Steven S., et al.
Publicado: (2021)

Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry
por: Murray, M. J., et al.
Publicado: (2020)

Geneticin Stabilizes the Open Conformation of the 5′ Region of Hepatitis C Virus RNA and Inhibits Viral Replication
por: Ariza-Mateos, Ascensión, et al.
Publicado: (2016)

Essential Roles for Soluble Virion-Associated Heparan Sulfonated Proteoglycans and Growth Factors in Human Papillomavirus Infections
por: Surviladze, Zurab, et al.
Publicado: (2012)

MBZM-N-IBT, a Novel Small Molecule, Restricts Chikungunya Virus Infection by Targeting nsP2 Protease Activity In Vitro, In Vivo, and Ex Vivo
por: De, Saikat, et al.
Publicado: (2022)

In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile
por: Oka, Daisuke, et al.
Publicado: (2021)

Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin
por: Somovilla, Pilar, et al.
Publicado: (2023)

Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses
por: Good, Steven S., et al.
Publicado: (2021)

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro
por: Acosta, Rima K., et al.
Publicado: (2022)

A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality
por: Fernández-Cruz, Ana, et al.
Publicado: (2020)

Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water
por: Gillman, Anna, et al.
Publicado: (2015)

In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles
por: Bowman, Emily R., et al.
Publicado: (2020)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5′-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase
por: Lu, Gaofei, et al.
Publicado: (2018)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System
por: Moure, Ricardo, et al.
Publicado: (2018)

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
por: Krishnan, Preethi, et al.
Publicado: (2018)

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens
por: Squires, Katherine E., et al.
Publicado: (2020)

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
por: Krishnan, Preethi, et al.
Publicado: (2018)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
por: Ng, Teresa I., et al.
Publicado: (2017)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
por: Ng, Teresa I., et al.
Publicado: (2017)

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial
por: Merchante, Nicolás, et al.
Publicado: (2022)

The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses
por: Xu, Na, et al.
Publicado: (2020)

High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses
por: Shen, Liang, et al.
Publicado: (2019)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d2453jthg4q8cjcj28ico0dtl4